Figure 3.

Plasma NfL increases throughout presymptomatic and symptomatic disease phases

(A) Longitudinal NfL concentrations are depicted for the indicated phenotype groups. NfL in plasma samples was measured in duplicate, and the mean concentration of replicates is shown on the base 10 logarithm scale.

(B) For individuals with one or more serial NfL measurements at least 1 year from baseline, we show comparisons of rate of change in NfL concentration per year for controls, all presymptomatic mutation carriers (all PreSx), presymptomatic carriers who did not convert (non-conv), those that did phenoconvert (phenoconv), and patients with MCI, bvFTD, PPA, or parkinsonian disorders. p values from analysis comparing rates of NfL change between the indicated group and either controls, non-converters, or phenoconverters after adjusting for age and gender are shown.

The number of individuals per group (n) is shown in figure panels and in Tables 1 and S1. See also Tables S13 and S14.